269 related articles for article (PubMed ID: 8923849)
1. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.
Papapoulos SE; Frölich M
J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849
[TBL] [Abstract][Full Text] [Related]
2. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
3. Urinary collagen crosslink excretion: a better index of bone resorption than hydroxyproline in Paget's disease of bone?
Hamdy NA; Papapoulos SE; Colwell A; Eastell R; Russell RG
Bone Miner; 1993 Jul; 22(1):1-8. PubMed ID: 8219934
[TBL] [Abstract][Full Text] [Related]
4. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
[TBL] [Abstract][Full Text] [Related]
5. Paget's disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate.
Filipponi P; Cristallini S; Policani G; Casciari C; Gregorio F
Bone; 1998 Dec; 23(6):543-8. PubMed ID: 9855463
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate.
O'Doherty DP; Bickerstaff DR; McCloskey EV; Hamdy NA; Beneton MN; Harris S; Mian M; Kanis JA
J Bone Miner Res; 1990 May; 5(5):483-91. PubMed ID: 2195845
[TBL] [Abstract][Full Text] [Related]
7. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.
Garnero P; Gineyts E; Riou JP; Delmas PD
J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361
[TBL] [Abstract][Full Text] [Related]
8. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
de la Piedra C; Rapado A; Díaz Diego EM; Díaz Martín MA; Aguirre C; López Gavilanes E; Díaz Curiel M
Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976
[TBL] [Abstract][Full Text] [Related]
9. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone.
Garnero P; Christgau S; Delmas PD
Bone; 2001 May; 28(5):461-4. PubMed ID: 11344044
[TBL] [Abstract][Full Text] [Related]
10. Acute effects of bisphosphonates on new and traditional markers of bone resorption.
Pedrazzoni M; Alfano FS; Gatti C; Fantuzzi M; Girasole G; Campanini C; Basini G; Passeri M
Calcif Tissue Int; 1995 Jul; 57(1):25-9. PubMed ID: 7671161
[TBL] [Abstract][Full Text] [Related]
11. [Deoxypyridinoline and other biochemical markers of bone resorption in distinct pathologies].
Rivero Marcotegui A; Palacios Sarrasqueta M; Grijalba Uche A; Martínez Rodríguez JL; Sorbet Zubiría MJ; García Merlo S
Rev Clin Esp; 1997 Jun; 197(6):389-92. PubMed ID: 9304127
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.
Alvarez L; Guañabens N; Peris P; Vidal S; Ros I; Monegal A; Bedini JL; Deulofeu R; Pons F; Muñoz-Gomez J; Ballesta AM
Bone; 2001 Nov; 29(5):447-52. PubMed ID: 11704497
[TBL] [Abstract][Full Text] [Related]
13. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links.
Randall AG; Kent GN; Garcia-Webb P; Bhagat CI; Pearce DJ; Gutteridge DH; Prince RL; Stewart G; Stuckey B; Will RK; Retallack RW; Price RI; Ward L
J Bone Miner Res; 1996 Aug; 11(8):1176-84. PubMed ID: 8854254
[TBL] [Abstract][Full Text] [Related]
14. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.
Alvarez L; Peris P; Pons F; Guañabens N; Herranz R; Monegal A; Bedini JL; Deulofeu R; Martínez de Osaba MJ; Muñoz-Gómez J; Ballesta AM
Arthritis Rheum; 1997 Mar; 40(3):461-8. PubMed ID: 9082934
[TBL] [Abstract][Full Text] [Related]
15. Short-term intravenous therapy with Neridronate in Paget's disease.
Adami S; Bevilacqua M; Broggini M; Filipponi P; Ortolani S; Palummeri E; Ulivieri F; Nannipieri F; Braga V
Clin Exp Rheumatol; 2002; 20(1):55-8. PubMed ID: 11892710
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate.
Adami S; Salvagno G; Guarrera G; Montesanti F; Garavelli S; Rosini S; Lo Cascio V
Calcif Tissue Int; 1986 Oct; 39(4):226-9. PubMed ID: 2947663
[TBL] [Abstract][Full Text] [Related]
17. Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone.
Garnero P; Fledelius C; Gineyts E; Serre CM; Vignot E; Delmas PD
J Bone Miner Res; 1997 Sep; 12(9):1407-15. PubMed ID: 9286756
[TBL] [Abstract][Full Text] [Related]
18. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).
Harinck HI; Papapoulos SE; Blanksma HJ; Moolenaar AJ; Vermeij P; Bijvoet OL
Br Med J (Clin Res Ed); 1987 Nov; 295(6609):1301-5. PubMed ID: 3120987
[TBL] [Abstract][Full Text] [Related]
19. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion.
Garnero P; Gineyts E; Arbault P; Christiansen C; Delmas PD
J Bone Miner Res; 1995 Apr; 10(4):641-9. PubMed ID: 7610936
[TBL] [Abstract][Full Text] [Related]
20. Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate.
Schweitzer DH; Zwinderman AH; Vermeij P; Bijvoet OL; Papapoulos SE
J Bone Miner Res; 1993 Feb; 8(2):175-82. PubMed ID: 8442435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]